Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Jeil develops new combo for Flomax & Vesicare
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Jun 25, 2014 01:49:18
Jeil will start its phase I clinical trial of JLP-1207, a combination drug of tamsulosin (Harnal) and solifenacin (Vesicare) to treat both benign prostate hyperplasia (BPH) and overactive bladder (OAB) as the Ministry of Food and Drug gave green light recently.

Jeil’s trial will be conducted in Seoul National University Medical Center to evaluate the interaction between those two drugs.

Jeil is the first company that tries a combo drug to treat BPH and OAB. Jeil has experiences with urologists through the co-marketing with MSD Korea.

As it takes three years for Vesicare to go off patent, more drugmakers may get interested in this kind of combination.

As the population is aging, the urology drug market is growing two by double digits every year.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com